IPHA-HSE Framework Agreement on Medicine Pricing 2026-2029 (ipha.ie)

• Framework sets pricing rules for medicines reimbursed by HSE from 2026 to 2029
• Prices for on-patent medicines realigned downward to average of nominated EU states
• UK included in first realignment basket (May 2026), excluded thereafter
• New medicines subject to price realignment after 36 months on market
• Agreement includes provisions for biosimilars, generics, and supply continuity

"The 2026-2029 IPHA-HSE Framework Agreement on the Supply and Pricing of Medicines sets rules for pricing of new and existing medicines, including realignment to EU reference countries and downward-only price adjustments. It covers patent-protected and biosimilar medicines, with provisions for continuity of supply and patient access schemes."